BABosede Bukola Afolabi

Bosede Bukola Afolabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bosede Bukola Afolabi has a total of 290 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial

    by Bosede B Afolabi, Victoria O Adaramoye, Titilope A Adeyemo, Mobolanle Balogun, Ajibola I Abioye, Eleanor J Mitchell, Aduragbemi Banke-Thomas, Kate F Walker, Ochuwa A Babah, Opeyemi R Akinajo, et al.

  • Open Access

    Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy in Nigeria (PIPSICKLE): a randomised controlled trial

    by Bosede Bukola Afolabi, Ochuwa Adiketu Babah, Yusuf Abisowo Oshodi, Ajibola Ibraheem Abioye, Gbenga Olorunfemi, Monsuru Owolabi Badmus, Hameed Adelabu, Rachel Thompson, Oluwakemi Odukoya, Veronica Chinyere Ezeaka, et al.


  • Open Access

    Azithromycin use in labour to prevent sepsis among pregnant women undergoing vaginal delivery in Nigeria (AZIN-V): a study protocol for a hybrid type 2 effectiveness-implementation trial

    by Bosede Bukola Afolabi, Christian Chigozie Makwe, Esther Oluwakemi Oluwole, Chisom Obi-Jeff, Eleanor J Mitchell, Aduragbemi Banke-Thomas, Titilope Adenike Adeyemo, Ajibola Ibraheem Abioye, Ejemai Amaize Eboreime, Abdulhadi Diyo Saidu, et al.

    Introduction: Nigeria has the highest number of maternal deaths globally, and maternal peripartum sepsis is one of the leading causes of maternal mortality. A single oral dose of azithromycin (AZM; 2 g) is safe and effectively reduces 33%–60% of maternal sepsis during planned vaginal birth in low- and middle-income countries (LMICs). However, the clinical and cost-effectiveness of oral AZM during vaginal birth in Nigeria remains unknown in the context of poor antimicrobial stewardship practices, significant antimicrobial resistance and healthcare financing. Evidence is also lacking on the standard care for the prevention of maternal sepsis among pregnant women undergoing vaginal births in Nigeria. The AZIN-V trial is a hybrid type 2 effectiveness-implementation trial to determine the safety, clinical and cost-effectiveness of intrapartum oral AZM versus usual care in the prevention of peripartum maternal sepsis. The trial will also examine the impact of implementation strategies in enhancing adherence to the oral AZM protocol during planned vaginal births and identify effective strategies to improve adherence (fidelity) to the protocol in real-world LMIC settings. Methods and analysis: This is a multicentre hybrid type 2 trial conducted in six Nigerian states: Ebonyi, Edo, Gombe, Kano, Kwara and Lagos. The study aims to simultaneously test the clinical and cost-effectiveness of AZM (clinical trial) and the impact of implementation strategies (implementation research) in Nigeria’s unique healthcare context. The clinical trial is a two-arm, cluster-randomised controlled trial conducted across 48 health facilities, randomly assigned (1:1) to either intrapartum administration of oral AZM (intervention group) or usual care—the current routine practice (control group). A total of 5040 study participants (2520 in each group) will be enrolled in the clinical trial. The implementation trial is a two-arm cluster non-randomised controlled trial conducted in 12 health facilities (1:1) allocated to either a bottom-up approach using the Plan-Do-Study-Act cycle or a usual top-down approach with a one-time training workshop and distribution of clinical guidelines, with both arms administering oral AZM during vaginal birth while assessing fidelity (primary outcome). For the clinical trial, data will be analysed using intention-to-treat statistical methods. The cost-effectiveness outcome will be analysed using the Incremental Cost-Effectiveness Ratio. Implementation outcomes will be analysed using descriptive statistics and a thematic approach. Ethics and dissemination: This study has been approved by the National Health Research Ethics Committee, Nigeria (NHREC/01/01/2007-30/09/2024), the ethics committees of the participating health institutions (Lagos University Teaching Hospital Research Ethics Committee: ADM/DSCST/HREC/APP/6325; University of Ilorin Teaching Hospital Health Research Ethics Committee: ERC/PAN/2025/03/0581; University of Benin Teaching Hospital Health Research Ethics Committee: ADM/E22/A/VOL. VII/483117141; Aminu Kano Teaching Hospital Research Ethics Committee: AKTH/MAC/SUB/12 A/P-3/VI/2509 and Irrua Specialist Teaching Hospital Research Ethics Committee: ISTH/HREC/20241507/605), the Ministries of Health of the six states and the National Agency for Food and Drug Administration and Control. Written informed consent will be obtained from all eligible study participants before enrolment. Results will be shared with communities and policy stakeholders and through peer-reviewed journals and will be presented at conferences. Trial registration number: ISRCTN16415327 .

  • Open Access

    Implementation of Routine Screening Practices for Pregnancy‐Related Anaemia: A Scoping Review

    by Yusuf Adelabu, Iana Malasevskaia, Mobolanle Balogun, Victoria Adaramoye, Lenka Benova, Bosede Afolabi, Aduragbemi Banke-Thomas

    Background: Screening for anaemia in pregnancy and the postpartum period is an important component of maternal care to prevent associated morbidity and mortality. However, the implementation of routine screening practices for pregnancy‐related anaemia remains variable, inconsistent, and suboptimal. This review aimed to synthesise the literature on practices, facilitators, barriers, implementation strategies, and outcomes of routine screening for pregnancy‐related anaemia. Methods: This scoping review followed the JBI methodology and PRISMA‐ScR checklist with a comprehensive systematic search of seven academic databases (PubMed, EMBASE, Scopus, CINAHL, Web of Science, Global Index Medicus, and African Journals Online) and selected grey literature sources. Retrieved citations were screened, and relevant references were assessed for eligibility. Articles included were analysed qualitatively and presented descriptively by concept, comparing settings with high and low prevalence of anaemia in pregnancy. Results: We identified 9497 references and included 116 articles in this review. Clinical practice guidelines recommend universal screening for anaemia during pregnancy and selective screening in the postpartum period using automated or point‐of‐care haemoglobin testing and iron studies, with variations in screening frequency and timing. Screening coverage for anaemia in pregnancy was lower in high‐prevalence compared to low‐prevalence settings. Effective supportive supervision was the main facilitator of anaemia screening in pregnancy, while lack of screening materials served as the main barrier, particularly in high‐prevalence settings. Training health workers on point‐of‐care testing in high‐prevalence settings was the most common strategy used to improve the implementation of routine screening for anaemia in pregnancy, and its feasibility was the most studied implementation outcome. Conclusion: Implementing routine screening practices for pregnancy‐related anaemia in all settings will benefit from harmonised clinical practice guidelines. Efforts are required to address implementation challenges and move from the early phase of implementation towards sustainability. Future research should aim to fill the knowledge gaps in implementing anaemia screening, particularly in the postpartum period.

  • Open Access

    Integrating a single-dose intravenous iron therapy (ferric carboxymaltose) for maternal anaemia in Nigeria: Insights from stakeholder engagement

    by Rachel A. Thompson, Uchenna Gwacham-Anisiobi, Chisom Obi-Jeff, Mobolanle Balogun, Opeyemi R. Akinajo, Esther Oluwole, Yusuf Adelabu, Temitope Audu, Bosede B. Afolabi, Aduragbemi Banke-Thomas

    Background: Maternal anaemia contributes to high maternal morbidity and adverse birth outcomes in Nigeria. Oral iron supplementation is common but limited by poor adherence, side effects and systemic barriers. Ferric carboxymaltose (FCM), a single-dose intravenous iron formulation, offers a promising alternative, yet its routine use in Nigeria remains limited. Policymakers, providers and community leaders influence adoption of health services, making their perspectives key to successful integration. Aim: To explore stakeholder perspectives on integrating FCM for maternal anaemia into routine maternal health services. Setting: The study was conducted in Lagos State, Nigeria. Methods: A qualitative descriptive study was conducted. Thirty-three purposively selected stakeholders participated, representing government agencies, healthcare providers, academic institutions, non-governmental organisations, professional associations and community leaders. Participants were grouped by affiliation and roles to encourage open dialogue. Discussions followed a semi-structured guide, were audio-recorded, transcribed verbatim and thematically analysed using an inductive approach. Results: Three interrelated themes emerged: (1) health workers are not sufficiently prepared for intravenous iron delivery but could be through sensitisation, reorientation and resourcing; (2) sociocultural and religious influences, alongside misconceptions, require targeted community engagement and (3) affordability is a barrier but could be addressed through strategic policy levers. Conclusion: Successful integration of FCM requires investment in health system capacity, sustained community engagement and alignment with financing and policy frameworks. Contribution: The findings illustrate how stakeholder-informed analysis can reveal the practical, cultural and financial conditions necessary for sustainable uptake of FCM, advancing understanding of how maternal health innovations can be integrated within fragmented health systems.

  • New WHO recommendations on the management of sickle‐cell disease in pregnancy

    by Myfanwy J. Williams, Jenny A. Ramson, Bosede B. Afolabi, Doris Chou


  • Open Access

    Time of onset of pre-eclampsia as a determinant of risk of cardiovascular disease and renal impairment at six weeks post partum: a cohort study in Lagos, Nigeria

    by Olaniyi Araotan Kusamotu, Ochuwa Adiketu Babah, Ifeoma Udenze, Ayodeji A Oluwole, Bosede Bukola Afolabi

    Objectives Pre-eclampsia causes significant maternal and perinatal morbidity and mortality. It also causes changes in the cardiovascular, endothelial and metabolic systems, from which women may not fully recover after delivery. This study examined the association between the time of onset of pre-eclampsia and the risk for cardiovascular disease (using glucose tolerance, lipid profile and blood pressure) and renal function at 6 weeks post partum. Study design A prospective cohort study. Setting Lagos University Teaching Hospital, Idi-Araba, Mother and Child Centre, Gbaja, Surulere and Lagos Island Maternity Hospital, Lagos, Nigeria. Participants 44 women with pre-eclampsia were studied and data on their sociodemographic characteristics, gestational age at diagnosis and blood pressure were collected on admission. They were followed up through delivery till 6 weeks post partum, when blood pressure check, 75 g oral glucose tolerance test, fasting lipid profile and serum creatinine were done. Outcome measures The exposure was pre-eclampsia. The outcomes were cardiovascular disease risk markers, viz persistent hypertension, glucose intolerance and dyslipidaemia, and renal function at 6 weeks post partum in women who had pre-eclampsia. Statistical analysis Data were analysed using Stata V.16.1. Mann Whitney-U test was used to compare medians and Fisher's exact test was used to compare the categorical variables. Results Of the women studied, 13 (29.5%) had early onset pre-eclampsia and 31 (70.5%) had late onset pre-eclampsia. Mean gestational age at diagnosis was 30.8±1.57 weeks in women with early-onset pre-eclampsia and 35.6±1.26 weeks in women with late-onset pre-eclampsia (pConclusion The prevalence of persistent hypertension at 6 weeks post partum is high in women with pre-eclampsia. Serum triglyceride concentration was significantly higher in early onset compared with late onset pre-eclampsia; subsequent studies powered to determine the full cardiovascular risk and how long to follow postnatal women up will be beneficial.


  • Open Access

    Unravelling the conundrums of social autopsy for maternal mortality in low- and middle-income countries

    by Aduragbemi Banke-Thomas, Adedoyin Ogunyemi, Adeyemi Okunowo, Ololade Wright, Celso Monjane, Fatimat M. Akinlusi, Brenda Isikekpei, Phillip Wanduru, Rachel A. Thompson, Ndubuisi Ezumezu, et al.


  • Open Access

    Author Correction: Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial

    by Demilade A. Adedinsewo, Andrea Carolina Morales-Lara, Bosede B. Afolabi, Oyewole A. Kushimo, Amam C. Mbakwem, Kehinde F. Ibiyemi, James Ayodele Ogunmodede, Hadijat Olaide Raji, Sadiq H. Ringim, Abdullahi A. Habib, et al.


  • Top Cited Papers
    Open Access

    Intravenous versus oral iron for anaemia among pregnant women in Nigeria (IVON): an open-label, randomised controlled trial

    by Bosede B Afolabi, Ochuwa A Babah, Titilope A Adeyemo, Mobolanle Balogun, Aduragbemi Banke-Thomas, Ajibola I Abioye, Opeyemi R Akinajo, Hadiza S Galadanci, Rachel A Quao, Hameed Adelabu, et al.